Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Hongo7-3-1, Bunkyo-ku, Tokyo, 113-0033, Japan.
Mod Rheumatol. 2010 Jun;20(3):233-7. doi: 10.1007/s10165-009-0262-1. Epub 2010 Jan 8.
The aim of this study was to investigate changes in the treatment strategy of rheumatoid arthritis (RA) and the prevalence of RA-related surgeries after approval of biologics in Japan and to analyze the impact of biologics on the incidence of orthopedic surgeries using a nationwide observational cohort database of rheumatic diseases [National Database of Rheumatic Diseases by iR-net in Japan (NinJa)]. The proportion of patients using biologics linearly increased from 2004 (1.8%) to 2007 (10.0%), but neither the number nor type of RA-related surgery significantly changed during this period. Patients treated with biologics exhibited relatively more severe disease activity and lower physical function. Among patients using biologics, those who underwent RA-related surgeries exhibited background characteristics of longer disease duration and worse physical function, while disease activity was not different from patients without surgery. These results suggest that the potential value of biologics in avoiding surgical procedure is limited in patients with severe functional disorders caused by long disease duration. Further investigation with a longer observation period is required to obtain more definite conclusions as to the impact of biologics usage on orthopedic surgeries.
本研究旨在探讨日本生物制剂批准后类风湿关节炎(RA)治疗策略的变化以及与 RA 相关手术的流行情况,并利用日本风湿疾病 iR-net 全国观察性队列数据库(NinJa)分析生物制剂对骨科手术发病率的影响。使用生物制剂的患者比例从 2004 年(1.8%)线性增加到 2007 年(10.0%),但在此期间,与 RA 相关的手术数量和类型均无显著变化。使用生物制剂治疗的患者表现出相对更严重的疾病活动和较低的身体功能。在使用生物制剂的患者中,接受 RA 相关手术的患者具有更长的疾病持续时间和更差的身体功能的背景特征,而疾病活动与未手术的患者没有差异。这些结果表明,对于由于疾病持续时间长而导致严重功能障碍的患者,生物制剂在避免手术方面的潜在价值有限。需要更长的观察期进一步研究,以获得关于生物制剂使用对骨科手术影响的更明确结论。